BETHESDA, Md., June 14 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the fourth quarter and fiscal year ended March 31, 2010.
Financial Highlights:
-- Revenue of $171.2 million in the fiscal year 2010
-- Operating income up 76.6% year over year to $14.4 million in the fiscal
year 2010
-- Net income up 65% year over year to $8.2 million in the fiscal year
2010, or $0.52 per diluted share, from $5.0 million, or $0.31 per
diluted share in the prior year
Roberta Lipson, President and CEO of Chindex, commented, "We are pleased with our fiscal year 2010 financial results in which we demonstrated steady growth in Healthcare Services of 8% and increased profitability for the firm as a whole. We remain enthusiastic about the healthcare services and medical device market opportunity in China, particularly with the confluence we see in China right now, specifically economic development, government support for leading providers and consumer demand for premium care."
Fourth Quarter 2010 Financial Results
Revenue in the fourth quarter of fiscal year 2010 decreased 30.9% to $41.3 million from $59.7 million in the fourth quarter of fiscal year 2009, reflecting continued growth in Healthcare Services offset by revenue performance in the Medical Products division. Revenue from the Healthcare Services division increased 4.9% to $21.2 million from $20.2 million in the fourth quarter of fiscal year 2009, and reflected growing inpatient and outpatient volume across the network despite construction-related disruption at the Company's Beijing facility. Consistent with prior quarters, Chindex expects the impact of the expansion work to continue through the opening of the expanded facilities, currently planned for the fall of 2010. Revenue from the Medical Products division was down 49.1% to $20.1 million from $39.5 million in the prior year period. The Company believes that the Ministry of Health Class A review process and timing, along with a general uncertainty around healthcare reform and expenditure, undermined this division's performance in the fourth quarter of fiscal 2010.
Income from operations in the fourth quarter of fiscal year 2010 was $1.1 million, compared to income from operations of $3.9 million in the same quarter last year. Total operating costs and expenses for the fourth quarter of fiscal year 2010 decreased 28.1% to $40.1 million from $55.8 million in the prior year period, primarily reflecting the decrease of 52.2% in product sales costs to $14.6 million in the fourth quarter of 2010. Operating costs also included $236,000 of development and startup expenses for new clinics, equivalent to $0.01 per diluted share, and non-cash stock compensation expense of $853,000 or $0.05 per diluted share. In the prior year period, the Company's development and startup expense were $536,000, or $0.03 per diluted share, and non-cash stock compensation expense was $848,000, or $0.05 per diluted share.
The Company recorded a $791,000 provision for taxes, an effective tax rate of 60.6%, in the fourth quarter of fiscal year 2010 as compared to a provision for taxes of $615,000, or an effective tax rate of 15.3%, in the prior year period. The tax rate reflects losses in entities for which the Company cannot yet recognize a benefit.
Net income for the quarter ended March 31, 2010 was $515,000, or $0.04 per diluted share. This compares to net income of $3.4 million, or $0.22 per diluted share, in the prior year period.
Healthcare Services division business results:
In the fourth quarter of fiscal year 2010, revenue increased 4.9% to $21.2 million from $20.2 million in the prior year period. The increase reflects growing inpatient and outpatient volume across the Company's network offset by near-term disruption related to expansion construction in Beijing.
In the fourth quarter of fiscal year 2010, operating costs were flat on a year over year basis at $18.8 million, and income from operations before foreign exchange loss increased 75.4% to $2.4 million from $1.3 million in the prior year period.
Lipson continued, "Our growth this quarter was consistent with our expectations and reflects continued demand for services across our network, offset slightly by construction-related disruption at our Beijing facility, where we are more than doubling our capacity by calendar year-end. We moved several exciting projects forward this quarter including officially launching the New Hope Oncology Center, entering design phase for the new facility in Tianjin, as well as meeting further demand for our services in Shanghai and Guangzhou. Overall, we remain uniquely positioned as a leading premium provider in China's healthcare services space and we are looking forward to more progress in the fiscal year ahead."
Medical Products division business results:
For the fourth quarter of fiscal year 2010, revenue was $20.1 million, down 49.1% from $39.5 million in the prior year period. Revenue performance mainly reflects the Ministry of Health's Class A review process and timing, which impacts daVinci order flow, along with a general uncertainty around healthcare reform and expenditure, which impacts overall demand and order for medical devices.
Gross profit for the Medical Products division was $5.5 million, compared to $9.0 million in the prior year period. Gross margin was 28% compared to 23% in the prior year period, in line with historical averages and revenue mix. Selling, marketing, general and administrative expenses for the Medical Products division decreased to $5.9 million from $6.3 million in the fourth quarter of the prior year.
Revenue from the Medical Products division was $85.4 million in the fiscal year 2010, a decrease of 7.2% from $92.1 million in the prior year. Gross profit in the division was $23.4 million, which yielded a gross margin of 27%, compared to $23.1 million, which yielded a gross margin of 25%, in the fiscal year 2009. Selling, marketing, general and administrative expenses for the Medical Products division increased 5.2% to $23.7 million from $22.6 million in the prior year, reflecting the increased selling activity.
Lipson added, "Despite the temporary challenges in our Medical Products division, we believe the medical device market in China remains extremely compelling. We believe order and shipment delays related to the regulatory review of high-value technologies is a temporary reality which substantiates the overall demand in the market for these products. Additionally, we are delighted to announce today our strategic partnership with Fosun Pharmaceuticals, a transformative event for Chindex and for our Medical Products division in particular."
Full Year 2010 Financial Results
During the fiscal year 2010, revenue remained flat on a year over year basis at $171.2 million, compared to $171.4 million in the prior year. Revenue from the Healthcare Services division increased 8.1% to $85.8 million from $79.4 million in fiscal year 2009. Revenue from the Medical Products division was $85.4 million, down 7.2% from $92.1 million in the prior year.
Income from operations increased 76.6% to $14.4 million for the full year ended March 31, 2010, from $8.2 million in the prior year. Total operating costs and expenses for the fiscal year 2010 decreased 4.0% to $156.8 million from $163.3 million in the prior year.
The Company recorded a $6.1 million provision for taxes, or an effective tax rate of 42.6%, in the fiscal year 2010, compared to a provision for taxes of $2.7 million, or an effective tax rate of 35.1%, for the fiscal year 2009.
In the fiscal year 2010, net income increased 65.3% to $8.2 million, or $0.52 per diluted share, from $5.0 million, or $0.31 per diluted share, in the prior year. Non-cash stock compensation expense was $3.3 million during the fiscal year 2010 compared to $2.9 million in the prior year.
Fourth Quarter Fiscal 2010 Conference Call
Management will host a conference call today at 8:00 am ET to discuss financial results.
To participate in the conference call, international callers should dial 1-760-666-3567 and domestic callers should dial 1-877-303-9231 approximately 10 minutes before the conference call is scheduled to begin.
The telephone replay will be available from the day of the call at (international) 1-706-645-9291 and (domestic) 1-800-642-1687, passcode 79429622.
This call is also being webcast and will be accessible at Chindex's website: http://ir.chindex.com/events.cfm . The event will be archived and available for replay through June 28, 2010.
About Chindex International, Inc.
Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and http://www.unitedfamilyhospitals.com .
Safe Harbor Statement
Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in our annual report on Form 10-K for the year ended March 31, 2009, updates and additions to those "Risk Factors" in our interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue" or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have no obligation to update these forward-looking statements.
For further information, please contact:
ICR, LLC
Ashley M. Ammon
Tel: +1-646-277-1227
CHINDEX INTERNATIONAL, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(in thousands except share and per share data)
(Unaudited)
Three months ended March31 Year ended March 31
2010 2009 2010 2009
Product sales $20,088 $39,478 $85,413 $92,085
Healthcare services
revenue 21,168 20,186 85,778 79,357
Total revenue 41,256 59,664 171,191 171,442
Cost and expenses
Product sales costs 14,553 30,451 62,059 69,027
Healthcare services costs 17,666 17,498 66,467 67,084
Selling and marketing
expenses 3,752 3,693 14,361 13,284
General and administrative
expenses 4,152 4,161 13,892 13,888
Income from operations 1,133 3,861 14,412 8,159
Other (expenses) and
income
Interest expense (199) (266) (983) (1,004)
Interest income 137 422 1,487 1,738
Miscellaneous income
(expense) - net 235 15 (616) (1,242)
Income before income taxes 1,306 4,032 14,300 7,651
Provision for income taxes (791) (615) (6,096) (2,687)
Net income $515 $3,417 $8,204 $4,964
Net income per common
share - basic $.04 $.24 $.56 $.34
Weighted average shares
outstanding - basic 14,721,901 14,479,237 14,579,759 14,410,033
Net income per common
share - diluted $.04 $.22 $.52 $.31
Weighted average shares
outstanding - diluted 16,188,973 15,744,153 16,132,339 16,021,723
CHINDEX INTERNATIONAL, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands except share data)
March 31, 2010 March 31, 2009
ASSETS
Current assets:
Cash and cash equivalents $50,654 $20,293
Restricted cash 468 1,854
Investments 37,207 51,502
Accounts receivable, less allowance
for doubtful accounts of $6,158 and
$5,041,respectively
Product sales receivables 22,760 37,994
Patient service receivables 10,357 8,837
Inventories, net 14,411 11,346
Deferred income taxes 2,843 2,410
Other current assets 3,032 3,239
Total current assets 141,732 137,475
Restricted cash 2,556 1,437
Property and equipment, net 23,678 20,633
Noncurrent deferred income taxes 103 1,031
Other assets 2,774 2,061
Total assets $170,843 $162,637
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term debt, current portion of
long-term debt and vendor financing $1,453 $1,631
Current portion of capitalized leases -- 22
Accounts payable 13,979 12,259
Accrued expenses 14,022 21,141
Other current liabilities 3,826 3,614
Deferred revenue 2,549 1,539
Income taxes payable 2,218 1,568
Total current liabilities 38,047 41,774
Long-term debt, vendor financing and
convertible debentures 22,593 23,709
Long-term accrued liabilities 84 --
Long-term deferred revenue 968 595
Long-term deferred tax liability 240 119
Total liabilities 61,932 66,197
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value,
500,000 shares authorized, none
issued -- --
Common stock, $.01 par value,
28,200,000 shares authorized,
including 3,200,000 designated
Class B:
Common stock - 13,765,857 and
13,452,007 shares issued and
outstanding at March 31, 2010 and
March 31, 2009, respectively 138 135
Class B stock - 1,162,500 shares
issued and outstanding at March 31,
2010 and March 31, 2009,
respectively 12 12
Additional paid-in capital 100,269 95,808
Accumulated other comprehensive
income 3,016 3,072
Retained earnings (accumulated
deficit) 5,476 (2,587)
Total stockholders' equity 108,911 96,440
Total liabilities and stockholders'
equity $170,843 $162,637
CHINDEX INTERNATIONAL, INC.
SEGMENT INFORMATION
The Company operates in two businesses: Healthcare Services and Medical
Products. The Company evaluates performance and allocates resources
based on profit or loss from operations before income taxes, not
including foreign exchange gains or losses.
(in thousands except share data)
Healthcare Medical
Services Products Total
For the three months ended March 31,
2010:
Sales and service revenue $21,168 $20,088 $41,256
Gross Profit n/a * 5,535 n/a
Gross Profit % n/a * 28% n/a
Income (loss) from operations before
foreign exchange $2,351 $(393) $1,958
Foreign exchange (loss) (825)
Income from operations $1,133
Other income, net 173
Income before income taxes $1,306
As of March 31, 2010:
Assets $112,929 $57,914 $170,843
Healthcare Medical
Services Products Total
For the three months ended March 31,
2009:
Sales and service revenue $20,186 $39,478 $59,664
Gross Profit n/a * 9,027 n/a
Gross Profit % n/a * 23% n/a
Income from operations before foreign
exchange $1,340 $2,693 $4,033
Foreign exchange (loss) (172)
Income from operations $3,861
Other income, net 171
Income before income taxes $4,032
As of March 31, 2009:
Assets $94,675 $67,962 $162,637
Healthcare Medical
Services Products Total
For the twelve months ended March 31,
2010:
Sales and service revenue $85,778 $85,413 $171,191
Gross Profit n/a * 23,354 n/a
Gross Profit % n/a * 27% n/a
Income (loss) from operations before
foreign exchange $14,393 $(366) $14,027
Foreign exchange gain 385
Income from operations $14,412
Other (expense), net (112)
Income before income taxes $14,300
As of March 31, 2010:
Assets $112,929 $57,914 $170,843
Healthcare Medical
Services Products Total
For the twelve months ended March 31,
2009:
Sales and service revenue $79,357 $92,085 $171,442
Gross Profit n/a * 23,058 n/a
Gross Profit % n/a * 25% n/a
Income from operations before foreign
exchange $7,309 $508 $7,817
Foreign exchange gain 342
Income from operations $8,159
Other (expense), net (508)
Income before income taxes $7,651
As of March 31, 2009:
Assets $94,675 $67,962 $162,637
